ERBB2 and malignant colon neoplasm: For this reason, to further evaluate the antitumor efficacy of refametinib plus pictilisib as a therapeutic strategy for HER2-amplified colon cancer we used patients derived tumor xenografts (PDTXs), by selecting three representative cases (CRC 1432, CRC 1430 and CRC 0186) of HER2-amplified tumors from mCRC patients [17].